Plus   Neg

Man Group Q3 FUM Rises Sequentially - Quick Facts

Man Group plc (MNGPF.PK,MNGPY.PK,EMG.L) reported Friday that its third-quarter funds under management or FUM was $113.1 billion as of September 30, a growth of 4 percent from preceding second quarter's $108.3 billion.

The company said the growth was driven by net inflows of $1.7 billion primarily from alternative strategies as redemption levels normalised following COVID-19 related rebalancing in the previous quarter.

Positive investment performance of $1.7 billion was largely from its long-only strategies, and positive FX and other movements of $1.4 billion resulted from a weaker US dollar particularly against sterling and the euro.

Alternative FUM grew to $72.4 billion from $69.4 billion in the second quarter.

Luke Ellis, Chief Executive Officer of Man Group, said, "This was driven by robust net inflows into alternatives as anticipated, as well as performance gains across both alternative and long-only strategies. Engagement with clients remains good, although there is increasing uncertainty due to upcoming political events and current COVID-19 trends."

Further, the company said its $100 million share buyback programme announced in September is proceeding at the maximum permitted pace.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT